Anocca

About

Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.

Södertälje,Vasternorrlands Lan,Sweden
11 - 50
https://www.anocca.com/

Highlights

Details

Last Funding Type: Debt Financing
Last Funding Money Raised: €25M
Industries: Biotechnology,Health Care,Therapeutics
Founded date: Oct 23, 2014
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Anocca AB

Anocca provides services like biotechnology, immunotherapeutics, drug discovery, drug development, and immunology services.

The company does precise and efficient analysis of T-cell biology, which is required to deliver a variety of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, assisting the life sciences sector in developing a variety of therapies and vaccination strategies.

Anocca was established on October 23, 2014 by Reagan Jarvis in Södertälje, Vasternorrlands Lan.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

€25M $47M

Anocca has raised a total of €25M $47M in funding over 2 rounds. Their latest funding was raised on Dec 21, 2022 from a Debt Financing round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 21, 2022	Debt Financing	€25M	1	European Investment Bank	—	Detail
Jul 22, 2021	Series B	$47M	5	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

6

Anocca is funded by 6 investors. European Investment Bank and Harald Mix are the most recent investors.

Investor Name	Lead Investor	Funding Round
European Investment Bank	Yes	Debt Financing
Harald Mix	—	Series B
Nidoco	—	Series B
Ramsbury Invest AB	—	Series B
Robert Andreen	—	Series B
Swedbank Robur’s Ny Teknik	—	Series B